Value of digital breast tomosynthesis in evaluating tumor size after neoadjuvant chemotherapy
Objective To evaluate the ability of digital breast tomosynthesis(DBT),full-field digital mammography(FFDM)and ultrasound(US)to predict residual tumor size after neoadjuvant chemotherapy.Methods The clinical and imaging data of patients who were diagnosed as breast cancer by pathological findings and received neoadjuvant chemotherapy and surgery from January 1,2020 to December 31,2021 were analyzed retrospectively.All patients underwent breast DBT,FFDM and US examinations after neoadjuvant chemotherapy.Pearson correlation analysis was used to calculate the correlation between residual tumor size measured by different imaging methods and pathological measurement results;the accuracy of different imaging examinations in predicting residual tumor size was analyzed with 0.5 cm as the threshold.Results A total of 86 lesions were included in 85 patients,and 72 lesions were included after removing the lesions without residual cancer after neoadjuvant chemotherapy.After neoadjuvant chemotherapy,the residual tumor size measured by DBT,FFDM and US was moderately correlated with the pathological measurement results.The accuracy of DBT,FFDM and US in predicting residual tumor size was 59.72％(43/72),43.06％(31/72)and 41.67％(30/72),respectively.The accuracy of DBT in predicting residual tumor size was significantly different from that of FFDM and US(y2=4.003,4.695;P=0.045,0.030).Conclusion After neoadjuvant chemotherapy,the accuracy of DBT in predicting residual tumor size is better than that of FFDM and US.DBT has a good application prospect in preoperative evaluation after neoadjuvant chemotherapy.
breast cancerdigital breast tomosynthesisfull-field digital mammographyultrasoundneoadjuvant chemotherapy
万方数据
维普
